CompletedNCT05063201
Cariprazine and cocaine use during buprenorphine treatment
About this title
Cariprazine for Comorbid Cocaine and Opioid Use Disorder
Read the official source — NCT05063201Medication studyAges 18–65United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- PhiladelphiaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: August 5, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 26
- Sponsor
- Kyle Kampman
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05063201
- Official title
Show the full official title
A Phase 2a Randomized, Single-blind, Placebo-controlled Pilot Study to Evaluate the Impact of Cariprazine (1.5mg) on Cocaine Use in OUD-CocUD Patients on Buprenorphine-naloxone.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Philadelphia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Kyle Kampman.
Did this study involve medication?
Yes. The study involved medication, including Cariprazine 1.5 MG and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
